$1,318.00
This Market Spotlight report covers the Glioblastoma (GBM) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Glioblastoma (GBM) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Patient segmentation
8 Symptoms
8 Risk factors
9 Diagnosis
10 TREATMENT
10 Surgery
10 Radiation therapy
10 Chemotherapy
10 Tumor-treating fields (TTFs)
11 Targeted therapy
12 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
36 RECENT EVENTS AND ANALYST OPINION
36 DNX-2401 for Glioblastoma (November 20, 2020)
37 Omburtamab for Glioblastoma (October 16, 2020)
40 KEY UPCOMING EVENTS
41 KEY REGULATORY EVENTS
41 Three-Month Dry Spell For EU PRIME Scheme
41 Pioneering Japan Approval For Daiichi’s Oncolytic Virus In Glioma
42 PROBABILITY OF SUCCESS
43 LICENSING AND ASSET ACQUISITION DEALS
43 Calidi Signs Licenses With Three Academic Partners In Oncolytic Virus Therapy
43 Kazia Therapeutics Enters Collaboration With Cornell University
43 Yale Unveils Research Pact With D&D Pharmatech
43 Lineage, Immunomic Partner On Brain Cancer Immunotherapy
44 UroGen, Johns Hopkins Investigate Brain Cancer Immunotherapy
44 Simcere Picks Up Kazia’s Paxalisib In China-Plus Area
45 REVENUE OPPORTUNITY
46 CLINICAL TRIAL LANDSCAPE
47 Sponsors by status
48 Sponsors by phase
49 Recent events
51 BIBLIOGRAPHY
53 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of glioblastoma, 2019–28
19 Figure 2: Overview of pipeline drugs for glioblastoma in the US
19 Figure 3: Pipeline drugs for glioblastoma, by company
20 Figure 4: Pipeline drugs for glioblastoma, by drug type
20 Figure 5: Pipeline drugs for glioblastoma, by classification
37 Figure 6: DNX-2401 for Glioblastoma (November 20, 2020): Phase II – CAPTIVE/KEYNOTE-192 – w/Keytruda
39 Figure 7: Omburtamab for Glioblastoma (October 16, 2020): Phase II/III – 101 (Neuroblastoma Central Nervous System/Leptomeningeal Metastases)
40 Figure 8: Key upcoming events in glioblastoma
42 Figure 9: Probability of success in the solid tumors pipeline
46 Figure 10: Clinical trials in glioblastoma
46 Figure 11: Top 10 drugs for clinical trials in glioblastoma
47 Figure 12: Top 10 companies for clinical trials in glioblastoma
47 Figure 13: Trial locations in glioblastoma
48 Figure 14: Glioblastoma trials status
49 Figure 15: Glioblastoma trials sponsors, by phase
LIST OF TABLES
13 Table 1: Global incident cases of glioblastoma, 2019–28
15 Table 2: Incident cases of glioblastoma, by gender, 2019
17 Table 3: Marketed drugs for glioblastoma
21 Table 4: Pipeline drugs for glioblastoma in the US
36 Table 5: DNX-2401 for Glioblastoma (November 20, 2020)
38 Table 6: Omburtamab for Glioblastoma (October 16, 2020)
45 Table 7: Historical global sales, by drug ($m), 2017–21
45 Table 8: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!